78 related articles for article (PubMed ID: 20861141)
1. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii.
Chopra S; Torres-Ortiz M; Hokama L; Madrid P; Tanga M; Mortelmans K; Kodukula K; Galande AK
J Antimicrob Chemother; 2010 Dec; 65(12):2598-601. PubMed ID: 20861141
[TBL] [Abstract][Full Text] [Related]
2. Cryo-electron Microscopy Structure of the Acinetobacter baumannii 70S Ribosome and Implications for New Antibiotic Development.
Morgan CE; Huang W; Rudin SD; Taylor DJ; Kirby JE; Bonomo RA; Yu EW
mBio; 2020 Jan; 11(1):. PubMed ID: 31964740
[TBL] [Abstract][Full Text] [Related]
3. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii.
Liu G; Catacutan DB; Rathod K; Swanson K; Jin W; Mohammed JC; Chiappino-Pepe A; Syed SA; Fragis M; Rachwalski K; Magolan J; Surette MG; Coombes BK; Jaakkola T; Barzilay R; Collins JJ; Stokes JM
Nat Chem Biol; 2023 Nov; 19(11):1342-1350. PubMed ID: 37231267
[TBL] [Abstract][Full Text] [Related]
4. Structure-based identification of novel inhibitors targeting the enoyl-ACP reductase enzyme of Acinetobacter baumannii.
Khan S; Madhi SA; Olwagen C
Sci Rep; 2023 Dec; 13(1):21331. PubMed ID: 38044353
[TBL] [Abstract][Full Text] [Related]
5. Repurposing FDA-approved drugs for anti-aging therapies.
Snell TW; Johnston RK; Srinivasan B; Zhou H; Gao M; Skolnick J
Biogerontology; 2016 Nov; 17(5-6):907-920. PubMed ID: 27484416
[TBL] [Abstract][Full Text] [Related]
6. The "PepSAVI-MS" Pipeline for Natural Product Bioactive Peptide Discovery.
Kirkpatrick CL; Broberg CA; McCool EN; Lee WJ; Chao A; McConnell EW; Pritchard DA; Hebert M; Fleeman R; Adams J; Jamil A; Madera L; Strömstedt AA; Göransson U; Liu Y; Hoskin DW; Shaw LN; Hicks LM
Anal Chem; 2017 Jan; 89(2):1194-1201. PubMed ID: 27991763
[TBL] [Abstract][Full Text] [Related]
7. FDA approves new antibiotic combination for drug-resistant pneumonia.
Mullard A
Nat Rev Drug Discov; 2023 Jul; 22(7):527. PubMed ID: 37286780
[No Abstract] [Full Text] [Related]
8. New Antibiotics for Resistant Infections: What Happens After Approval?
Howard-Anderson J; Boucher HW
Ann Intern Med; 2024 May; 177(5):674-675. PubMed ID: 38639541
[No Abstract] [Full Text] [Related]
9. Reimagining the Past: A Future for Antibiotic Drug Discovery in Ophthalmology.
Chen ER; Wozniak RAF
Cornea; 2024 Jan; 43(1):1-5. PubMed ID: 37702607
[TBL] [Abstract][Full Text] [Related]
10. When Still Water Runs Deep: The Complexities of Clinically Repurposing FDA Approved Therapies.
Beninger P; Maron J
Clin Ther; 2022 Nov; 44(11):1427-1430. PubMed ID: 36411115
[No Abstract] [Full Text] [Related]
11. Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant
Cheng YS; Sun W; Xu M; Shen M; Khraiwesh M; Sciotti RJ; Zheng W
Front Cell Infect Microbiol; 2018; 8():438. PubMed ID: 30662875
[TBL] [Abstract][Full Text] [Related]
12. Drug Repurposing Approach for Developing Novel Therapy Against Mupirocin-Resistant
Mujwar S; Deshmukh R; Harwansh RK; Gupta JK; Gour A
Assay Drug Dev Technol; 2019 Oct; 17(7):298-309. PubMed ID: 31634019
[No Abstract] [Full Text] [Related]
13. Farnesol repurposing for prevention and treatment of
Tan L; Ma R; Katz AJ; Levi N
Biofilm; 2024 Jun; 7():100198. PubMed ID: 38706984
[No Abstract] [Full Text] [Related]
14. Combination of AS101 and Mefloquine Inhibits Carbapenem-Resistant
Li R; Shen X; Li Z; Shen J; Tang H; Xu H; Shen J; Xu Y
Infect Drug Resist; 2023; 16():7271-7288. PubMed ID: 38023412
[TBL] [Abstract][Full Text] [Related]
15. Preferential Selection of Low-Frequency, Lipopolysaccharide-Modified, Colistin-Resistant Mutants with a Combination of Antimicrobials in Acinetobacter baumannii.
Kamoshida G; Yamada N; Nakamura T; Yamaguchi D; Kai D; Yamashita M; Hayashi C; Kanda N; Sakaguchi M; Morimoto H; Sawada T; Okada T; Kaya Y; Takemoto N; Yahiro K
Microbiol Spectr; 2022 Oct; 10(5):e0192822. PubMed ID: 36173297
[TBL] [Abstract][Full Text] [Related]
16. Creating Robust Antimicrobial Materials with Sticky Tyrocidines.
van Rensburg W; Rautenbach M
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203778
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Organotellurium Compound AS101 for Treating Colistin- and Carbapenem-Resistant
Yang TY; Kao HY; Lu PL; Chen PY; Wang SC; Wang LC; Hsieh YJ; Tseng SP
Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451891
[TBL] [Abstract][Full Text] [Related]
18. An Oral Fluorouracil Prodrug, Capecitabine, Mitigates a Gram-Positive Systemic Infection in Mice.
McLeod JR; Harvey PA; Detweiler CS
Microbiol Spectr; 2021 Sep; 9(1):e0027521. PubMed ID: 34190602
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Antimicrobial and Antibiofilm Effect of New Colistin-Loaded Human Albumin Nanoparticles.
Scutera S; Argenziano M; Sparti R; Bessone F; Bianco G; Bastiancich C; Castagnoli C; Stella M; Musso T; Cavalli R
Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33430076
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-Resistant
Ayerbe-Algaba R; Gil-Marqués ML; Jiménez-Mejías ME; Sánchez-Encinales V; Parra-Millán R; Pachón-Ibáñez ME; Pachón J; Smani Y
Front Cell Infect Microbiol; 2018; 8():348. PubMed ID: 30338245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
